信立泰：SAL0140片临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0140, aimed at treating primary aldosteronism [1] Group 1: Drug Development - SAL0140 is a self-developed aldosterone synthase inhibitor with independent intellectual property rights [1] - The drug is intended to address indications including uncontrolled hypertension (including resistant hypertension), primary aldosteronism, and chronic kidney disease (CKD) [1]